{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:10:42Z","timestamp":1778659842781,"version":"3.51.4"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/BI\/25\/012\/2012"],"award-info":[{"award-number":["BT\/BI\/25\/012\/2012"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020970","name":"Rashtriya Uchchatar Shiksha Abhiyan","doi-asserted-by":"publisher","award":["RUSA 2 .0"],"award-info":[{"award-number":["RUSA 2 .0"]}],"id":[{"id":"10.13039\/501100020970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020970","name":"Rashtriya Uchchatar Shiksha Abhiyan","doi-asserted-by":"publisher","award":["F. 24-51\/2014-U"],"award-info":[{"award-number":["F. 24-51\/2014-U"]}],"id":[{"id":"10.13039\/501100020970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.brainres.2025.149674","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:00:38Z","timestamp":1746723638000},"page":"149674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic Targeting of Autosomal Parkinson\u2019s Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein"],"prefix":"10.1016","volume":"1860","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-1002","authenticated-orcid":false,"given":"Zeeshan","family":"Hyderi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Farhana M","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tej Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arumugam Veera","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2025.149674_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102067","article-title":"Neuroepigenetics of ageing and neurodegeneration-associated dementia: an updated review","volume":"91","author":"Mir","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.brainres.2025.149674_b0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/0118744710314668240718070109","article-title":"Recent advances in the diagnosis of Alzheimer\u2019s disease: a brief overview of Tau PET tracers in nuclear medicine","volume":"18","author":"Aghahosseini","year":"2024","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.brainres.2025.149674_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102357","article-title":"Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance","volume":"99","author":"Gadhave","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.brainres.2025.149674_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0025","article-title":"Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis","volume":"3\u201326","author":"Kouli","year":"2018","journal-title":"Park. Dis. Pathog. Clin. Asp."},{"key":"10.1016\/j.brainres.2025.149674_b0030","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/brain\/aws023","article-title":"Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?","volume":"135","author":"Helmich","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.brainres.2025.149674_b0035","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson\u2019s disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2025.149674_b0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.arr.2014.01.004","article-title":"Ageing and Parkinson\u2019s disease: why is advancing age the biggest risk factor?","volume":"14","author":"Reeve","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.brainres.2025.149674_b0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s Disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainres.2025.149674_b0050","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/cells12050764","article-title":"Recent advances in the treatment of genetic forms of Parkinson\u2019s disease: hype or hope?","volume":"12","author":"Cavallieri","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0055","article-title":"Genetics of Parkinson\u2019s disease: dominant forms and GBA","volume":"4","author":"Salles","year":"2024","journal-title":"Neurol. Perspect."},{"issue":"9","key":"10.1016\/j.brainres.2025.149674_b0060","first-page":"1","article-title":"LRRK2 kinase regulates \u03b1-synuclein propagation via RAB35 phosphorylation","volume":"91","author":"Bae","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-012-0984-y","article-title":"LRRK2 interactions with \u03b1-synuclein in Parkinson\u2019s disease brains and in cell models","volume":"91","author":"Guerreiro","year":"2013","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.brainres.2025.149674_b0070","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2174\/1570159X16666180222165418","article-title":"The Role of LRRK2 in Neurodegeneration of Parkinson Disease","volume":"16","author":"Rui","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.brainres.2025.149674_b0075","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1042\/BCJ20190664","article-title":"PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72","volume":"477","author":"Vieweg","year":"2020","journal-title":"Biochem. J."},{"key":"10.1016\/j.brainres.2025.149674_b0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/bies.200900163","article-title":"Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau","volume":"32","author":"Taymans","year":"2010","journal-title":"Bioessays"},{"key":"10.1016\/j.brainres.2025.149674_b0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1212\/01.wnl.0000277637.33328.d8","article-title":"The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?","volume":"69","author":"Orr-Urtreger","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.brainres.2025.149674_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-1-17","article-title":"LRRK2 in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"1","author":"Zhu","year":"2006","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.brainres.2025.149674_b0095","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/mds.28189","article-title":"Nonsteroidal anti-inflammatory use and LRRK2 Parkinson\u2019s disease penetrance","volume":"35","author":"San Luciano","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149674_b0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.28411","article-title":"Genetic and environmental factors in Parkinson\u2019s disease converge on immune function and inflammation","volume":"36","author":"Kline","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149674_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22031045","article-title":"Genetic and environmental factors influence the pleomorphy of LRRK2 Parkinsonism","volume":"22","author":"Chittoor-Vinod","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0110","doi-asserted-by":"crossref","unstructured":"L\u00fcth, T., et al. 2023. Interaction of mitochondrial polygenic score and environmental factors in LRRK2 p.Gly2019Ser parkinsonism. medRxiv 2023.01.02.23284113 (2023) doi:10.1101\/2023.01.02.23284113.","DOI":"10.1002\/mds.29563"},{"key":"10.1016\/j.brainres.2025.149674_b0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BST20180462","article-title":"LRRK2 links genetic and sporadic Parkinson\u2019s disease","volume":"47","author":"Kluss","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.brainres.2025.149674_b0120","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.778","article-title":"Computational analysis of the LRRK2 interactome","volume":"3","author":"Manzoni","year":"2015","journal-title":"PeerJ"},{"key":"10.1016\/j.brainres.2025.149674_b0125","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ana.25692","article-title":"Longitudinal positron emission tomography of dopamine synthesis in subjects with GBA1 mutations","volume":"87","author":"Lopez","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0130","article-title":"Physiological and pathological functions of LRRK2: implications from substrate proteins. Neuronal","volume":"2","author":"Araki","year":"2018","journal-title":"Signal."},{"key":"10.1016\/j.brainres.2025.149674_b0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fnins.2020.00376","article-title":"Multiple-hit hypothesis in Parkinson\u2019s disease: LRRK2 and inflammation","volume":"14","author":"Cabezudo","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00498","article-title":"LRRK2: autophagy and lysosomal activity","volume":"14","author":"Madureira","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0145","doi-asserted-by":"crossref","unstructured":"Komori T, Kuwahara T. An Update on the Interplay between LRRK2, Rab GTPases and Parkinson's Disease. Biomolecules. 2023 Nov 13;13(11):1645. doi: 10.3390\/biom13111645. PMID: 38002327; PMCID: PMC10669493.","DOI":"10.3390\/biom13111645"},{"key":"10.1016\/j.brainres.2025.149674_b0150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/archneurol.2010.79","article-title":"LRRK2 and Parkinson disease","volume":"67","author":"D\u00e4chsel","year":"2010","journal-title":"Arch. Neurol."},{"issue":"588","key":"10.1016\/j.brainres.2025.149674_b0155","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction","volume":"5887837","author":"Deniston","year":"2020","journal-title":"Nat."},{"key":"10.1016\/j.brainres.2025.149674_b0160","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jnr.21949","article-title":"Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson\u2019s disease","volume":"87","author":"Gandhi","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.brainres.2025.149674_b0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","article-title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease","volume":"298","author":"West","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0170","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.molmed.2024.07.003","article-title":"LRRK2 in Parkinson\u2019s disease: upstream regulation and therapeutic targeting","volume":"30","author":"Xiong","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.brainres.2025.149674_b0175","first-page":"1","article-title":"Pathways to Parkinson\u2019s disease: a spotlight on 14-3-3 proteins","volume":"71","author":"Giusto","year":"2021","journal-title":"Npj Park. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0180","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-030122-051144","article-title":"Leucine-rich repeat kinases","volume":"93","author":"Alessi","year":"2024","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.brainres.2025.149674_b0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-319-49969-7_4","article-title":"Understanding the GTPase activity of LRRK2: regulation, function, and neurotoxicity","volume":"14","author":"Nguyen","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.brainres.2025.149674_b0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21541248.2016.1276999","article-title":"Molecular control of Rab activity by GEFs Gaps and GDI","volume":"9","author":"M\u00fcller","year":"2017","journal-title":"Small GTPases"},{"key":"10.1016\/j.brainres.2025.149674_b0195","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/biom13040612","article-title":"LRRK2 structure-based activation mechanism and pathogenesis","volume":"13","author":"Zhang","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.149674_b0200","doi-asserted-by":"crossref","first-page":"e00660","DOI":"10.1128\/MCB.00660-20","article-title":"The cell biology of LRRK2 in Parkinson\u2019s disease","volume":"41","author":"Usmani","year":"2021","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.brainres.2025.149674_b0205","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/biom13111645","article-title":"An Update on the Interplay between LRRK2 Rab GTPases and Parkinson\u2019s disease","volume":"13","author":"Komori","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.brainres.2025.149674_b0210","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.3390\/ijms19124074","article-title":"Roco proteins and the Parkinson\u2019s disease-associated LRRK2","volume":"19","author":"Liao","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0215","doi-asserted-by":"crossref","unstructured":"Wojewska, D.N., Kortholt, A., 2021. LRRK2 Targeting Strategies as Potential Treatment of Parkinson\u2019s Disease. Biomol. 2021, Vol. 11, Page 1101 11, 1101 (2021).","DOI":"10.3390\/biom11081101"},{"key":"10.1016\/j.brainres.2025.149674_b0220","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1111\/febs.13305","article-title":"Cellular processes associated with LRRK2 function and dysfunction","volume":"282","author":"Wallings","year":"2015","journal-title":"Febs J."},{"key":"10.1016\/j.brainres.2025.149674_b0225","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1042\/BST20180463","article-title":"LRRK2 regulation of immune-pathways and inflammatory disease","volume":"47","author":"Wallings","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.brainres.2025.149674_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165632","article-title":"The LRRK2-RAB axis in regulation of vesicle trafficking and \u03b1-synuclein propagation","volume":"1866","author":"Bae","year":"2020","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0235","first-page":"541","article-title":"LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism","volume":"128","author":"Arranz","year":"2015","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0240","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3233\/JPD-202138","article-title":"LRRK2 and the endolysosomal system in Parkinson\u2019s Disease","volume":"10","author":"Erb","year":"2020","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0245","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/hmg\/ddz201","article-title":"RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase-mediated centrosomal cohesion and ciliogenesis deficits","volume":"28","author":"Lara Ord\u00f3nez","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104476","article-title":"Pathogenic LRRK2 regulates centrosome cohesion via Rab10\/RILPL1-mediated CDK5RAP2 displacement","volume":"25","author":"Fdez","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.brainres.2025.149674_b0255","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2018.06.010","article-title":"LRRK2 and mitochondria: recent advances and current views","volume":"1702","author":"Singh","year":"2018","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.brainres.2025.149674_b0260","first-page":"1","article-title":"The role of macrophage plasticity in neurodegenerative diseases","volume":"121","author":"Ma","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.brainres.2025.149674_b0265","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259724","article-title":"Leucine-rich repeat kinase 2 at a glance","volume":"136","author":"Zhu","year":"2023","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0270","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s13311-021-01007-8","article-title":"LRRK2 ablation attenuates \u03b1lpha-synuclein-induced neuroinflammation without affecting neurodegeneration or neuropathology in vivo","volume":"18","author":"Van der Perren","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.brainres.2025.149674_b0275","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5607\/en.2018.27.3.171","article-title":"LRRK2 kinase activity induces mitochondrial fission in microglia via Drp1 and modulates neuroinflammation","volume":"27","author":"Ho","year":"2018","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.brainres.2025.149674_b0280","article-title":"The double-faceted role of leucine-rich repeat kinase 2 in the immunopathogenesis of Parkinson\u2019s disease","volume":"14","author":"Zhang","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"10.1016\/j.brainres.2025.149674_b0900","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.3390\/cimb46050263","article-title":"Expression of G2019S LRRK2 in Rat Primary Astrocytes Mediates Neurotoxicity and Alters the Dopamine Synthesis Pathway in N27 Cells via Astrocytic Proinflammatory Cytokines and Neurotrophic Factors","volume":"46","author":"Ho","year":"2024","journal-title":"Current Issues in Molecular Biology"},{"key":"10.1016\/j.brainres.2025.149674_b0285","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/19768354.2019.1585948","article-title":"G2019s LRRK2 promotes mitochondrial fission and increases TNF\u03b1-mediated neuroinflammation responses","volume":"23","author":"Ho","year":"2019","journal-title":"Animal Cells Syst. (Seoul"},{"key":"10.1016\/j.brainres.2025.149674_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131799","article-title":"LRRK2 kinase inhibition attenuates neuroinflammation and cytotoxicity in animal models of Alzheimer\u2019s and Parkinson\u2019s disease-related neuroinflammation","volume":"12","author":"Mutti","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050861","article-title":"LRRK2 inhibition mitigates the neuroinflammation caused by TLR2-specific \u03b1-synuclein and alleviates neuroinflammation-derived dopaminergic neuronal loss","volume":"11","author":"Ho","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.brainres.2025.149674_b0305","first-page":"1","article-title":"Interferon-\u03b3 signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells","volume":"111","author":"Panagiotakopoulou","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.brainres.2025.149674_b0310","first-page":"1","article-title":"Phosphorylation of AQP4 by LRRK2 R1441G impairs glymphatic clearance of IFN\u03b3 and aggravates dopaminergic neurodegeneration","volume":"101","author":"Huang","year":"2024","journal-title":"npj Park Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0315","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0320","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000488938","article-title":"Leucine-rich repeat kinase 2 in Parkinson\u2019s disease: updated from pathogenesis to potential therapeutic target","volume":"79","author":"Chen","year":"2018","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0325","article-title":"Cognitive impairment in genetic Parkinson\u2019s disease","volume":"2021","author":"Planas-Ballv\u00e9","year":"2021","journal-title":"Park. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0330","doi-asserted-by":"crossref","unstructured":"Ito, G., Utsunomiya-Tate, N., 2023. Overview of the impact of pathogenic LRRK2 mutations in Parkinson\u2019s Disease. Biomol. 2023, Vol. 13, Page 845 13, 845 (2023).","DOI":"10.3390\/biom13050845"},{"key":"10.1016\/j.brainres.2025.149674_b0335","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/hmg\/ddm151","article-title":"Mechanistic insight into the dominant mode of the Parkinson\u2019s disease-associated G2019S LRRK2 mutation","volume":"16","author":"Luz\u00f3n-Toro","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0340","doi-asserted-by":"crossref","unstructured":"Ravinther, A.I., et al., 2022. Molecular pathways involved in LRRK2-linked Parkinson\u2019s disease: a systematic review. Int. J. Mol. Sci. 2022, Vol. 23, Page 11744 23, 11744 (2022).","DOI":"10.3390\/ijms231911744"},{"key":"10.1016\/j.brainres.2025.149674_b0350","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.bbadis.2009.09.010","article-title":"The R1441C mutation alters the folding properties of the ROC domain of LRRK2","volume":"1792","author":"Li","year":"2009","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"issue":"8","key":"10.1016\/j.brainres.2025.149674_b0355","first-page":"1","article-title":"A homologue of the Parkinson\u2019s disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover","volume":"81","author":"Deyaert","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.brainres.2025.149674_b0360","first-page":"1","article-title":"The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions","volume":"71","author":"Carrion","year":"2017","journal-title":"Sci. Reports"},{"key":"10.1016\/j.brainres.2025.149674_b0365","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.3390\/ijms23126808","article-title":"LRRK2 and proteostasis in Parkinson\u2019s disease","volume":"23","author":"P\u00e9rez-Carri\u00f3n","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0370","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/0929866526666181208170027","article-title":"Leucine rich repeat proteins: sequences, mutations structures and diseases","volume":"26","author":"Matsushima","year":"2018","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.brainres.2025.149674_b0375","doi-asserted-by":"crossref","first-page":"17296","DOI":"10.1073\/pnas.1922184117","article-title":"Dopaminergic neurodegeneration induced by Parkinson\u2019s disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity","volume":"117","author":"Nguyen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.brainres.2025.149674_b0380","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.brainres.2025.149674_b0385","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/cdd.2012.42","article-title":"(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD","volume":"19","author":"Chen","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.brainres.2025.149674_b0390","article-title":"The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson\u2019s disease","volume":"10","author":"de Jacquet","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.brainres.2025.149674_b0395","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000289232","article-title":"Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation","volume":"7","author":"Wider","year":"2010","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0400","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1534\/genetics.118.301119","article-title":"Genetic modifiers of neurodegeneration in a drosophila model of Parkinson\u2019s disease","volume":"209","author":"Lavoy","year":"2018","journal-title":"Genetics"},{"key":"10.1016\/j.brainres.2025.149674_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.971252","article-title":"Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.brainres.2025.149674_b0410","first-page":"1","article-title":"LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients","volume":"101","author":"Ysselstein","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b0415","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/mds.26161","article-title":"Cognitive profile of LRRK2-related Parkinson\u2019s disease","volume":"30","author":"Srivatsal","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149674_b0420","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2016.00018","article-title":"Protective LRRK2 R1398H variant enhances GTPase and Wnt signaling activity","volume":"9","author":"Nixon-Abell","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0425","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1093\/hmg\/ddv314","article-title":"Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression","volume":"24","author":"Henry","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0430","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/hmg\/ddz088","article-title":"LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function","volume":"28","author":"Wallings","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3563","article-title":"Targeting Rab-RILPL interactions as a strategy to downregulate pathogenic LRRK2 in Parkinson\u2019s disease","volume":"30","author":"Alexander","year":"2024","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0445","article-title":"A pathogenic variant in RAB32 causes autosomal dominant Parkinson\u2019s disease and activates LRRK2 kinase","author":"Gustavsson","year":"2024","journal-title":"medRxiv Prepr Serv. Heal. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0450","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/1535370215579162","article-title":"LRRK2 mutations and neurotoxicant susceptibility","volume":"240","author":"Lee","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.brainres.2025.149674_b0455","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00674","article-title":"Progress in LRRK2-associated Parkinson\u2019s disease animal models","volume":"14","author":"Seegobin","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0460","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-022-00285-2","article-title":"LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson\u2019s disease","volume":"11","author":"Chang","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.149674_b0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022354","article-title":"Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans","volume":"6","author":"Yuan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2025.149674_b0470","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cell.2014.01.064","article-title":"Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson\u2019s disease","volume":"157","author":"Martin","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2025.149674_b0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2025.149674_b0480","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00577","article-title":"LRRK2 and \u03b1-synuclein: distinct or synergistic players in Parkinson\u2019s disease?","volume":"14","author":"O\u2019Hara","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0485","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303789120","article-title":"LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition","volume":"120","author":"Yadavalli","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.brainres.2025.149674_b0490","doi-asserted-by":"crossref","first-page":"9289","DOI":"10.1073\/pnas.1403215111","article-title":"Abrogation of \u03b1-synuclein -mediated dopaminergic neurodegeneration in LRRK2-deficient rats","volume":"111","author":"Daher","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.brainres.2025.149674_b0495","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg3555","article-title":"Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration","volume":"14","author":"Liu","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.brainres.2025.149674_b0500","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.nbd.2014.08.027","article-title":"Conditional expression of Parkinson\u2019s disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration","volume":"71","author":"Tsika","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0505","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/hmg\/dds431","article-title":"Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity","volume":"22","author":"Yao","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0510","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1093\/hmg\/ddx320","article-title":"LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson\u2019s disease","volume":"26","author":"Howlett","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"15","key":"10.1016\/j.brainres.2025.149674_b0520","first-page":"1","article-title":"Using computer modeling to find new LRRK2 inhibitors for parkinson\u2019s disease","volume":"151","author":"Garc\u00eda","year":"2025","journal-title":"Sci. Reports"},{"key":"10.1016\/j.brainres.2025.149674_b0525","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jconrel.2024.12.045","article-title":"In vivo self-assembled siRNAs within small extracellular vesicles attenuate LRRK2-induced neurodegeneration in Parkinson\u2019s disease models","volume":"378","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.brainres.2025.149674_b0530","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/ph15121546","article-title":"FDA-approved kinase inhibitors in preclinical and clinical trials for neurological disorders","volume":"15","author":"Lui","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.brainres.2025.149674_b0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbrc.2008.11.048","article-title":"Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2","volume":"378","author":"Covy","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b0540","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/bph.15575","article-title":"The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson\u2019s disease: the current state of play","volume":"179","author":"Azeggagh","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2025.149674_b0545","first-page":"177","article-title":"LRRK2 inhibitors and their potential in the treatment of Parkinson\u2019s disease: current perspectives","volume":"8","author":"Atashrazm","year":"2016","journal-title":"Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.brainres.2025.149674_b0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"162","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0555","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ml300123a","article-title":"Brain penetrant LRRK2 inhibitor","volume":"3","author":"Choi","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2025.149674_b0515","doi-asserted-by":"crossref","unstructured":"Logan KM, Kaplan W, Simov V, Zhou H, Li D, Torres L, Morriello GJ, Acton JJ, Pio B, Chen YH, Keylor MH, Johnson R, Kattar SD, Chau R, Yan X, Ardolino M, Zarate C, Otte KM, Palte RL, Xiong T, McMinn SE, Lin S, Neelamkavil SF, Liu P, Su J, Hegde LG, Woodhouse JD, Moy LY, Ciaccio PJ, Piesvaux J, Zebisch M, Henry C, Barker J, Wood HB, Kennedy ME, DiMauro EF, Fell MJ, Fuller PH. Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors. J Med Chem. 2024 Sep 26;67(18):16807-16819. doi: 10.1021\/acs.jmedchem.4c01627. Epub 2024 Sep 4. PMID: 39231262.","DOI":"10.1021\/acs.jmedchem.4c01627"},{"key":"10.1016\/j.brainres.2025.149674_b0345","doi-asserted-by":"crossref","unstructured":"Potdar C, Jagtap S, Singh K, Yadav R, Pal PK, Datta I. Impaired Sonic Hedgehog Responsiveness of Induced Pluripotent Stem Cell-Derived Floor Plate Cells Carrying the LRRK2-I1371V Mutation Contributes to the Ontogenic Origin of Lower Dopaminergic Neuron Yield. Stem Cells Dev. 2024 Jun;33(11-12):306-320. doi: 10.1089\/scd.2023.0283. Epub 2024 Jun 3. PMID: 38753688.","DOI":"10.1089\/scd.2023.0283"},{"key":"10.1016\/j.brainres.2025.149674_b0435","doi-asserted-by":"crossref","unstructured":"Ciampelli C, Galleri G, Galioto M, Mereu P, Pirastru M, Bernardoni R, Albani D, Crosio C, Iaccarino C. LRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease. Int J Mol Sci. 2025 Feb 27;26(5):2093. doi: 10.3390\/ijms26052093. PMID: 40076730; PMCID: PMC11900240.","DOI":"10.3390\/ijms26052093"},{"key":"10.1016\/j.brainres.2025.149674_b0560","unstructured":"Denali Therapeutics Announces Decision to Advance DNL151. https:\/\/www.globenewswire.com\/news-release\/2020\/08\/06\/2074205\/0\/en\/Denali-Therapeutics-Announces-Decision-to-Advance-DNL151-into-Late-Stage-Clinical-Studies-in-Parkinson-s-Patients.html."},{"key":"10.1016\/j.brainres.2025.149674_b0565","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149674_b0570","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.pmch.2016.11.002","article-title":"Development of LRRK2 inhibitors for the treatment of Parkinson\u2019s disease","volume":"56","author":"Christensen","year":"2017","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0575","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40035-022-00281-6","article-title":"LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson\u2019s disease","volume":"11","author":"Pang","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.brainres.2025.149674_b0580","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40265-019-01139-4","article-title":"Recent developments in LRRK2-targeted therapy for Parkinson\u2019s disease","volume":"79","author":"Zhao","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.brainres.2025.149674_b0585","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1016\/j.bmcl.2012.06.104","article-title":"GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor","volume":"22","author":"Reith","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.brainres.2025.149674_b0590","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-319-49969-7_13","article-title":"Small-Molecule Inhibitors of LRRK2","volume":"14","author":"Hatcher","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"10.1016\/j.brainres.2025.149674_b0595","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0600","doi-asserted-by":"crossref","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","article-title":"Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-synuclein gene-induced neurodegeneration","volume":"290","author":"Daher","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0605","doi-asserted-by":"crossref","unstructured":"Thakur G, Kumar V, Lee KW, Won C. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade. Genes (Basel). 2022 Aug 11;13(8):1426. doi: 10.3390\/genes13081426. PMID: 36011337; PMCID: PMC9408223.","DOI":"10.3390\/genes13081426"},{"key":"10.1016\/j.brainres.2025.149674_b0610","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0615","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.16265","article-title":"The kinase LRRK2 is required for the physiological function and expression of the glial glutamate transporter EAAT2 (SLC1A2)","volume":"169","author":"Di Iacovo","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2025.149674_b0620","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2025.149674_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114080","article-title":"Discovery of G2019S-Selective leucine rich repeat protein kinase 2 inhibitors with in vivo efficacy","volume":"229","author":"Le\u015bniak","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0630","doi-asserted-by":"crossref","first-page":"88442","DOI":"10.3389\/fnmol.2014.00051","article-title":"In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2","volume":"7","author":"Vancraenenbroeck","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0635","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.1021\/acs.jmedchem.1c00720","article-title":"Design and synthesis of Pyrrolo[2,3-d]pyrimidine-derived leucine-rich repeat kinase 2 (LRRK2) inhibitors using a checkpoint kinase 1 (CHK1)-derived crystallographic surrogate","volume":"64","author":"Williamson","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106906","article-title":"Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson\u2019s disease","volume":"141","author":"Cao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0645","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cells11061018","article-title":"A phosphosite mutant approach on LRRK2 links phosphorylation and dephosphorylation to protective and deleterious markers","volume":"11","author":"Marchand","year":"2022","journal-title":"Respectively. Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.149674_b0655","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., et al., 2023. Current Treatments and New, Tentative Therapies for Parkinson\u2019s Disease. Pharm. 2023, Vol. 15, Page 770 15, 770 (2023).","DOI":"10.3390\/pharmaceutics15030770"},{"key":"10.1016\/j.brainres.2025.149674_b0660","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s Disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0665","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3233\/JPD-239901","article-title":"Parkinson\u2019s Disease drug therapies in the clinical trial pipeline: 2023 update","volume":"13","author":"McFarthing","year":"2023","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0670","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70082","article-title":"Identification of potent leucine-rich repeat kinase 2 inhibitors by virtual screening and biological evaluation","volume":"105","author":"Shen","year":"2025","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.brainres.2025.149674_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021352","article-title":"Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi","volume":"6","author":"de Y\u00f1igo-Mojado","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.brainres.2025.149674_b0680","first-page":"1","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"51","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.brainres.2025.149674_b0685","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","article-title":"Repair of DNA double-strand breaks by the non-homologous end joining pathway","volume":"90","author":"Stinson","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.brainres.2025.149674_b0690","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.scr.2017.08.013","article-title":"CRISPR\/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and \u03b1-Synuclein modulation in dopaminergic neurons","volume":"24","author":"Qing","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.brainres.2025.149674_b0695","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1038\/s41598-020-60273-2","article-title":"In vitro CRISPR\/Cas9-directed gene editing to model LRRK2 G2019S Parkinson\u2019s disease in common marmosets","volume":"10","author":"Vermilyea","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.149674_b0700","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.3390\/ijms241310474","article-title":"LRRK2 knockout confers resistance in HEK-293 cells to rotenone-induced oxidative stress, mitochondrial damage, and apoptosis","volume":"24","author":"Quintero-Espinosa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0705","article-title":"RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors","author":"Dou","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.brainres.2025.149674_b0710","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042320","article-title":"Unraveling the genetic landscape of neurological disorders: insights into pathogenesis, techniques for variant identification, and therapeutic approaches","volume":"25","author":"Firdaus","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0715","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s13311-013-0233-2","article-title":"Gene-based therapies in Parkinson\u2019s disease","volume":"11","author":"Allen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.brainres.2025.149674_b0720","doi-asserted-by":"crossref","unstructured":"Chung, S.K., Lee, S.Y., 2022. Advances in Gene Therapy Techniques to Treat LRRK2 Gene Mutation. Biomol. 2022, Vol. 12, Page 1814 12, 1814 (2022).","DOI":"10.3390\/biom12121814"},{"key":"10.1016\/j.brainres.2025.149674_b0725","article-title":"CRISPR-Cas9 through AAV delivery system as a gene therapy in Parkinson\u00e2\u20acTMs disease","volume":"7","author":"Cahyono","year":"2023","journal-title":"Qanun Med. - Med. J. Fac. Med. Muhammadiyah Surabaya"},{"key":"10.1016\/j.brainres.2025.149674_b0730","article-title":"Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.149674_b0735","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.brainres.2025.149674_b0740","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.omtn.2020.06.027","article-title":"Splice-switching antisense oligonucleotides reduce LRRK2 kinase activity in human LRRK2 transgenic mice","volume":"21","author":"Korecka","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.brainres.2025.149674_b0745","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3390\/cells12162119","article-title":"Antisense therapy for infectious diseases","volume":"12","author":"Buthelezi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0750","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson\u2019s disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.brainres.2025.149674_b0755","first-page":"1","article-title":"In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease","volume":"91","author":"Price","year":"2023","journal-title":"npj Park Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0760","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00702-013-1008-y","article-title":"Treatment of Parkinson\u2019s disease in the advanced stage","volume":"120","author":"Ossig","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.brainres.2025.149674_b0765","doi-asserted-by":"crossref","DOI":"10.25259\/SNI_233_2020","article-title":"Mesenchymal stem cells in Parkinson\u2019s disease: motor and nonmotor symptoms in the early posttransplant period","volume":"11","author":"Boika","year":"2020","journal-title":"Surg. Neurol. Int."},{"key":"10.1016\/j.brainres.2025.149674_b0770","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.3390\/ijms22126389","article-title":"Adeno-associated viral vectors as versatile tools for Parkinson\u2019s research, both for disease modeling purposes and for therapeutic uses","volume":"22","author":"Fajardo-Serrano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.brainres.2025.149674_b0775","doi-asserted-by":"crossref","first-page":"937","DOI":"10.47197\/retos.v48.96771","article-title":"\u00bfEl tratamiento con ejercicios de Pilates de alta intensidad es beneficioso para las personas con enfermedad de Parkinson? (Is high intensity Pilates exercise treatment beneficial for people with Parkinso\u0144s disease?)","volume":"48","author":"Cardalda","year":"2023","journal-title":"Retos"},{"key":"10.1016\/j.brainres.2025.149674_b0780","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1007\/s12264-021-00730-8","article-title":"The relationship between the gut microbiome and neurodegenerative diseases","volume":"37","author":"Zhu","year":"2021","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.brainres.2025.149674_b0785","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00355","article-title":"Korean red ginseng enhances neurogenesis in the subventricular zone of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice","volume":"10","author":"Ryu","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0790","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81639-0","article-title":"Loss of Parkinson\u2019s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis","volume":"11","author":"Lebovitz","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainres.2025.149674_b0795","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097988","article-title":"Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955","volume":"9","author":"Ito","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2025.149674_b0800","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0820","article-title":"LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits","volume":"12","author":"Baptista","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.149674_b0805","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acschembio.1c00487","article-title":"Allosteric inhibition of Parkinson\u2019s-Linked LRRK2 by constrained peptides","volume":"16","author":"Helton","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.brainres.2025.149674_b0810","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.brainres.2025.149674_b0815","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40478-019-0679-5","article-title":"LRRK2 inhibition does not impart protection from \u03b1-synuclein pathology and neuron death in non-transgenic mice","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b0820","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1042\/BJ20141305","article-title":"LRRK2 dephosphorylation increases its ubiquitination","volume":"469","author":"Zhao","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.brainres.2025.149674_b0825","doi-asserted-by":"crossref","unstructured":"Lubben, N., et al., 2023. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread. bioRxiv 2023.10.06.561190 (2023) doi:10.1101\/2023.10.06.561190.","DOI":"10.1101\/2023.10.06.561190"},{"key":"10.1016\/j.brainres.2025.149674_b0830","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1021\/acs.jmedchem.4c00520","article-title":"Concurrent optimizations of efficacy and blood-brain barrier permeability in new macrocyclic LRRK2 inhibitors for potential parkinson\u2019s disease therapeutics","volume":"67","author":"Kim","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0835","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","article-title":"Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"55","author":"Estrada","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0840","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1016040","article-title":"Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson\u2019s disease and other diseases for which carriers are at increased risk","volume":"13","author":"Lesniak","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0845","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1042\/BCJ20210375","article-title":"Impact of type II LRRK2 inhibitors on signaling and mitophagy","volume":"478","author":"Tasegian","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.brainres.2025.149674_b0850","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1021\/acs.jmedchem.0c01243","article-title":"Selective inhibitors of G2019S-LRRK2 kinase activity","volume":"63","author":"Garofalo","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.brainres.2025.149674_b0855","first-page":"1","article-title":"Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation","volume":"61","author":"Lobbestael","year":"2016","journal-title":"Sci. Reports"},{"key":"10.1016\/j.brainres.2025.149674_b0860","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1093\/hmg\/dds342","article-title":"LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6","volume":"21","author":"Berwick","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.brainres.2025.149674_b0865","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.3233\/JPD-213138","article-title":"Inflammatory animal models of Parkinson\u2019s disease","volume":"12","author":"Garc\u00eda-Revilla","year":"2022","journal-title":"J. Parkinsons. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0870","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/cells12131799","article-title":"LRRK2 kinase inhibition attenuates neuroinflammation and cytotoxicity in animal models of Alzheimer\u2019s and Parkinson\u2019s disease-related neuroinflammation","volume":"12","author":"Mutti","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.brainres.2025.149674_b0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105607","article-title":"Primary cilia and ciliary signaling pathways in aging and age-related brain disorders","volume":"163","author":"Ma","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0880","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnmol.2014.00049","article-title":"LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex","volume":"7","author":"Cirnaru","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0885","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/hmg\/ddw194","article-title":"LRRK2 modulates microglial activity through regulation of chemokine (C\u2013X3\u2013C) receptor 1 \u2013mediated signalling pathways","volume":"25","author":"Ma","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.brainres.2025.149674_b0890","first-page":"1","article-title":"LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase","volume":"61","author":"Choi","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1337-8","article-title":"Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4","volume":"15","author":"Russo","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainres.2025.149674_b0905","article-title":"Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2025.149674_b0910","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2017.00125","article-title":"Leucine-rich repeat kinase 2 (LRRK2) stimulates IL-1\u03b2-mediated inflammatory signaling through phosphorylation of RCAN1","volume":"11","author":"Han","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b0915","doi-asserted-by":"crossref","first-page":"E5164","DOI":"10.1073\/pnas.1718946115","article-title":"Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson\u2019s disease","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.brainres.2025.149674_b0920","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8162","article-title":"An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis","volume":"10","author":"Takagawa","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.brainres.2025.149674_b0925","first-page":"1","article-title":"Perspective on the current state of the LRRK2 field","volume":"91","author":"Taymans","year":"2023","journal-title":"npj Park Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0930","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-97-0048-6_11","article-title":"Animal model for Alzheimer\u2019s Disease, Parkinson\u2019s disease, and schizophrenia","volume":"283\u2013317","author":"Dhanasekaran","year":"2024","journal-title":"Anim. Model. Res."},{"key":"10.1016\/j.brainres.2025.149674_b0935","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.3233\/JAD-220682","article-title":"Pathological and therapeutic advances in Parkinson\u2019s Disease: mitochondria in the interplay","volume":"94","author":"Naren","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.brainres.2025.149674_b0940","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/genes13081426","article-title":"Structural insights and development of LRRK2 inhibitors for Parkinson\u2019s disease in the last decade","volume":"13","author":"Thakur","year":"2022","journal-title":"Genes (Basel)."},{"key":"10.1016\/j.brainres.2025.149674_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115475","article-title":"Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives","volume":"256","author":"Hu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.brainres.2025.149674_b0950","article-title":"Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson\u2019s disease and other diseases for which carriers are at increased risk","volume":"13","author":"Kobeissy","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0955","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1016040","article-title":"Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson\u2019s disease and other diseases for which carriers are at increased risk","volume":"13","author":"Lesniak","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b0960","article-title":"Discovering biomarker proteins and peptides for Parkinson\u2019s disease prognosis prediction with machine learning and interpretability methods","author":"Park","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.brainres.2025.149674_b0965","doi-asserted-by":"crossref","unstructured":"Howey, K.D., Li, M., Christenson, P.R., Larsen, P.A., Oh, S.-H., 2024. AI-QuIC: machine learning for automated detection of misfolded proteins in seed amplification assays. bioRxiv 2024.10.16.618742 (2024) doi:10.1101\/2024.10.16.618742.","DOI":"10.1101\/2024.10.16.618742"},{"key":"10.1016\/j.brainres.2025.149674_b0970","doi-asserted-by":"crossref","unstructured":"Vlieger, R., Daskalaki, E., Apthorp, D., Lueck, C.J., Suominen, H., 2023. Evaluating effects of resting-state electroencephalography data pre-processing on a machine learning task for Parkinson\u2019s disease. medRxiv 2023.03.06.23286826 (2023) doi:10.1101\/2023.03.06.23286826.","DOI":"10.1101\/2023.03.06.23286826"},{"key":"10.1016\/j.brainres.2025.149674_b0975","doi-asserted-by":"crossref","DOI":"10.1515\/jib-2018-0063","article-title":"QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson\u2019s Disease","volume":"16","author":"Sebasti\u00e1n-P\u00e9rez","year":"2019","journal-title":"J. Integr. Bioinform."},{"issue":"6","key":"10.1016\/j.brainres.2025.149674_b0980","first-page":"1","article-title":"Inhibitor treatment of peripheral mononuclear cells from Parkinson\u2019s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker","volume":"61","author":"Perera","year":"2016","journal-title":"Sci. Reports"},{"key":"10.1016\/j.brainres.2025.149674_b0985","article-title":"Inhibition of Parkinson\u2019s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures","author":"Murillo","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.brainres.2025.149674_b0990","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104494","article-title":"LRRK 2 activation controls the repair of damaged endomembranes in macrophages","volume":"39","author":"Herbst","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.brainres.2025.149674_b0995","doi-asserted-by":"crossref","unstructured":"Dou, D., Smith, E.M., Evans, C.S., Boecker, C.A., Holzbaur, E.L.F., 2022. Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes. bioRxiv 2022.11.14.516471 (2022) doi:10.1101\/2022.11.14.516471.","DOI":"10.1101\/2022.11.14.516471"},{"key":"10.1016\/j.brainres.2025.149674_b1000","doi-asserted-by":"crossref","unstructured":"Dhekne, H.S., et al., 2023. Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase. bioRxiv 2023.02.17.529028 (2023) doi:10.1101\/2023.02.17.529028.","DOI":"10.1101\/2023.02.17.529028"},{"key":"10.1016\/j.brainres.2025.149674_b1005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/21541248.2019.1666623","article-title":"LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain","volume":"12","author":"McGrath","year":"2021","journal-title":"Small GTPases"},{"key":"10.1016\/j.brainres.2025.149674_b1010","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79771","article-title":"A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation","volume":"11","author":"Vides","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.brainres.2025.149674_b1015","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00227","article-title":"The emerging functions of LRRK2 and Rab GTPases in the endolysosomal system","volume":"14","author":"Kuwahara","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b1020","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.28490","article-title":"Differential inhibition of LRRK2 in Parkinson\u2019s disease patient blood by a G2019S selective LRRK2 inhibitor","volume":"36","author":"Bright","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.brainres.2025.149674_b1025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41531-022-00386-9","article-title":"Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain \u03b1-synuclein oligomers without adverse effects","volume":"8","author":"Ho","year":"2022","journal-title":"NPJ Park. Dis."},{"key":"10.1016\/j.brainres.2025.149674_b1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107614","article-title":"The Parkinson\u2019s disease protein LRRK2 interacts with the GARP complex to promote retrograde transport to the trans-golgi network","volume":"31","author":"Beilina","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.brainres.2025.149674_b1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102064","article-title":"ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages","volume":"34","author":"Wallings","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.brainres.2025.149674_b1040","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine rich repeat kinase 2 (LRRK2) protect against LRRK2-models of Parkinson\u2019s disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainres.2025.149674_b1045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/acn3.282","article-title":"Antioxidants inhibit neuronal toxicity in Parkinson\u2019s disease-linked LRRK2","volume":"3","author":"Angeles","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.brainres.2025.149674_b1050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jnc.12691","article-title":"LRRK2: Dropping (kinase) inhibitions and seeking an (immune) response","volume":"129","author":"Mamais","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2025.149674_b1055","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00442","article-title":"LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons","volume":"14","author":"Sanyal","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.brainres.2025.149674_b1060","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67604","article-title":"Pharmacological rescue of impaired mitophagy in parkinson\u2019s disease-related LRRK2 G2019S knock-in mice","volume":"10","author":"Singh","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.brainres.2025.149674_b1065","article-title":"Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: activity and structures","volume":"9","author":"Murillo","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.brainres.2025.149674_b1070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1570159X13666151030102847","article-title":"LRRK2 kinase inhibition as a therapeutic strategy for Parkinson\u2019s disease, where do we stand?","volume":"14","author":"Taymans","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.brainres.2025.149674_b1075","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1038\/s41467-018-05958-z","article-title":"LRRK2 kinase regulates \u03b1-synuclein propagation via RAB35 phosphorylation","volume":"9","author":"Bae","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.brainres.2025.149674_b1080","doi-asserted-by":"crossref","first-page":"E4357","DOI":"10.1073\/pnas.1523708113","article-title":"Structural model of the dimeric Parkinson\u2019s protein LRRK2 reveals a compact architecture involving distant interdomain contacts","volume":"113","author":"Guaitoli","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.brainres.2025.149674_b1085","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2014.00382","article-title":"Phosphatases of \u03b1-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism","volume":"5","author":"Taymans","year":"2014","journal-title":"Front. Genet."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325002331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325002331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:35:36Z","timestamp":1778657736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899325002331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":217,"alternative-id":["S0006899325002331"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149674","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Targeting of Autosomal Parkinson\u2019s Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149674"}}